- Conditions
- Enterotoxigenic E. Coli (ETEC) Infection
- Interventions
- ACE527 vaccine, Placebo vaccine
- Biological
- Lead sponsor
- TD Vaccines A/S
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 11,161
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NSCLC, Locally Advanced
- Interventions
- Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC)
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hodgkin Lymphoma
- Interventions
- Mocetinostat Plus Brentuximab Vedotin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fractional Flow Reserve, Myocardial, Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Centro Hospitalar Lisboa Ocidental
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Obecabtagene Autoleucel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Duarte, California • Stanford, California • Basking Ridge, New Jersey + 6 more
- Conditions
- Depression, Mood, Sleep, Physical Activity
- Interventions
- Intern Health Study behavioral change mobile notification
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,562 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Las Vegas, Nevada + 3 more
- Conditions
- Endometrial Cancer
- Interventions
- Hypofractionated Radiation, Clinical Follow-Up and Assessments
- Radiation · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more
- Conditions
- Risk Perceptions, Decision Making, Alcohol
- Interventions
- Health warning statement evaluations (bottles), Health warning statement evaluations (ads)
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Bacterial Infections
- Interventions
- RO7223280
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Louisville, Kentucky • Royal Oak, Michigan + 2 more
- Conditions
- Breast Augmentation, Breast Reconstruction, Breast Revision
- Interventions
- The Contour Profile Gel (CPG) breast implants
- Device
- Lead sponsor
- Mentor Worldwide, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,891 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Influenza, COVID-19, Communication Research, Health Behavior, Respiratory Viral Infection
- Interventions
- Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3, Science communication curriculum Cohort 4
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan
- Conditions
- Multicentric Castleman s Disease
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Interventions
- Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
- Interventions
- Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
- Other · Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
- Interventions
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Biological
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Pharmacokinetics
- Interventions
- PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
- Drug
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Vestibular Schwannoma
- Interventions
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Combination Product
- Lead sponsor
- Akouos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- Glioblastoma, Gliomas
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 3
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York
- Conditions
- High Grade Glioma
- Interventions
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Hepatic Impairment
- Interventions
- Radiprodil
- Drug
- Lead sponsor
- GRIN Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- DeSoto, Texas • San Antonio, Texas
- Conditions
- Parkinson's Disease
- Interventions
- Levodopa (delivered intravenously)
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Interventions
- SLC-391, pembrolizumab
- Drug · Biological
- Lead sponsor
- SignalChem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
- Conditions
- Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
- Interventions
- Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina